NCT05337189 A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China Status RECRUITING Phase N/A
NCT05335941 A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05321316 Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma Status RECRUITING Phase NA
NCT05302284 A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma Status RECRUITING Phase PHASE3
NCT05243550 A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05242822 A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations Status TERMINATED Phase PHASE1
NCT05239624 Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer Status RECRUITING Phase PHASE2
NCT05234606 A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors Status WITHDRAWN Phase PHASE1/PHASE2
NCT05229614 Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease Status RECRUITING Phase PHASE2
NCT05226117 Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer Status COMPLETED Phase PHASE2
NCT05200988 Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05137262 A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05136898 Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) Status COMPLETED Phase PHASE3
NCT05107427 Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma Status WITHDRAWN Phase PHASE2
NCT05086666 A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 Status UNKNOWN Phase PHASE1/PHASE2
NCT05078047 Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05070039 Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian Population Status COMPLETED Phase NA
NCT05052372 Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib Status TERMINATED Phase N/A